Association Between Serum Galectin-3 and Parkinson's Disease: A Two-Sample Mendelian Randomization Study.

Area of Science:

• Neuroscience
• Genetics
• Biomarker Discovery

Background:

• Parkinson's disease (PD) is a common neurodegenerative disorder with limited treatment options.
• Observational studies suggest a link between serum galectin-3 and PD, but a causal relationship remains unproven.

Purpose of the Study:

• To investigate the potential causal role of serum galectin-3 in the risk of developing Parkinson's disease using a Mendelian randomization approach.

Main Methods:

• A two-sample Mendelian randomization study utilized genetic variants associated with serum galectin-3 levels from a large genome-wide association study (GWAS).
• Summary statistics for Parkinson's disease were obtained from a separate, large-scale GWAS.
• Inverse-variance weighting (IVW) was the primary analysis method, with weighted median, MR-Egger, and MR-PRESSO used for sensitivity analyses to assess heterogeneity and pleiotropy.

Main Results:

• Consistent results across multiple MR methods (IVW, weighted median, weighted mode, MR-PRESSO) indicated that higher serum galectin-3 levels are significantly associated with an increased risk of Parkinson's disease.
• No evidence of heterogeneity or horizontal pleiotropy was detected, strengthening the findings.

Conclusions:

• The study provides evidence suggesting a causal association between elevated serum galectin-3 and an increased risk of Parkinson's disease.
• Galectin-3 may be a significant factor in the causal pathway of PD, positioning it as a potential therapeutic target or diagnostic biomarker.